Testing engineered immune cells for H3K27M diffuse midline glioma and DIPG
Original title: H3K27M-specific Immune Effector Cells Targeting DMG/DIPG
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people, done to check safety first.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests immune cells built to target a tumor change called H3K27M.
Who this trial is for. This trial is for people with high-risk diffuse midline glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary or DIPG whose tumor is H3K27M-positive. It tests immune effector cells that are engineered to target H3K27M.
Where it stands. The trial has not reported results. The team plans to look at how doable and how safe this treatment is, and how well it works. They also want to learn how these cells work in the body and how long they last.
What this means, and what it doesn't
What it could mean: This is one of the ideas being tested for H3K27M-positive tumors. Someone who fits this picture could ask their care team about it.
What it doesn't mean: This does not mean the treatment works. A trial is a test, not a proven treatment. Joining a trial is not a promise that it will help you. It is not a cure.
Source: ClinicalTrials.gov, August 27, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.